MercadoLibre (NASDAQ:MELI) might not be a household name in the U.S., but in-the-know investors should be familiar with it.The Latin American e-commerce company has been a juggernaut on the market, up ...
Elon Musk has always been something of a maverick in the technology industry. Tesla (NASDAQ: TSLA) was a major win, with Musk essentially creating the electric vehicle industry (EV). The CEO is ...
Nebius (NASDAQ: NBIS) is turning extraordinary demand for AI infrastructure into billion-dollar contracts, rapid revenue growth, and additional capacity.
IBM (NYSE: IBM) may have a multiyear opportunity hiding inside the shift to post-quantum security. The upside depends on whether IBM can turn its technical credibility and enterprise footprint into ...
Bristol Myers Squibb (NYSE: BMY) was created via the combination of companies founded in 1858 and 1887. It has a proven history of survival in the highly competitive and innovative pharmaceutical ...
Opinion
September Is Historically a Slow Month for Stocks. Here's Why That Shouldn't Matter to Investors
September usually isn't a great month for U.S. stocks. The S&P 500 (SNPINDEX: ^GSPC) has averaged a decline of roughly -0.6% in September since its inception, making it the only calendar month with a ...
Just over a year ago, Ripple CEO Brad Garlinghouse said XRP (CRYPTO: XRP) could take 14% of SWIFT's volume by 2030. That was ambitious when he said it, but today it seems almost impossible.
On August 24, 2026 Thailand issued bonds (TH0623A77280) in the amount of THB 20000 mln maturing in 2027.
On August 26, 2026 Pharmaron Beijing issued international bonds (XS3487780218) in the amount of CNY 2180 mln maturing in 2027. The issues were sold at the price of 102% at par.The bookrunners of the ...
Telsey Advisory raised its price target for Dollar General (NYSE:DG) to $140.00, maintaining a 'Market Perform' rating. Dollar General (NYSE:DG) exceeded expectations with a 5.2% increase in ...
The company, which, in its present incarnation, is a clinical-stage biotech, agreed to an impressive licensing and collaboration deal with a peer and secured a favorable judgment in a court case.
— We have everything you need: full data on over 1 000 000 bonds, 100 000 stocks, 100 000 indices, 17 000 ETF and 150 000 Mutual Funds; powerful bond screener; over 350 pricing sources among stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results